Clinical Trials
43 trialsStudy of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments
Ono Pharmaceutical Co., Ltd.
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Ascentage Pharma Group Inc.
PALANGI3
Centre Oscar Lambret
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Kura Oncology, Inc.
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Taiho Pharmaceutical Co., Ltd.
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Novartis
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
A Drug-drug Interaction Study of Avapritinib and Midazolam
Blueprint Medicines Corporation
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Deciphera Pharmaceuticals, LLC
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Ipilimumab and Imatinib Mesylate in Advanced Cancer
M.D. Anderson Cancer Center
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)
Daiichi Sankyo
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
A Bioequivalence Study of Sunitinib Malate Capsules.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Ludwig Institute for Cancer Research
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Blueprint Medicines Corporation
SURE
Dana-Farber Cancer Institute
A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
Novartis
ABILITY
Radboud University Medical Center
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
TG Therapeutics, Inc.
GIST
Mendus
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
Mayo Clinic
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
National Cancer Institute (NCI)
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
Asan Medical Center
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
Dong-A ST Co., Ltd.
TH-CR-410
Threshold Pharmaceuticals
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
Novartis
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
National Cancer Institute (NCI)
Imatinib
Chong Kun Dang Pharmaceutical
Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
Vanderbilt-Ingram Cancer Center
Phase 1 Study of OSI-930 in Cancer Patients
Astellas Pharma Inc
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
National Cancer Institute (NCI)
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
National Cancer Institute (NCI)
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NYU Langone Health
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
Infinity Pharmaceuticals, Inc.
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
Dana-Farber Cancer Institute
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center